REFRACTORY MANTLE CELL LYMPHOMA

This study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…

This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…

This study is testing whether two oral medications, venetoclax and acalabrutinib, can help control mantle cell lymphoma that has returned or didn't respond to previous treatments. The trial involves 32 adults who have already tried at least one other therapy. Researchers want to …

This early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…

This study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…

This study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…

This early-stage study is testing a new combination of three drugs (alisertib, bortezomib, and rituximab) for people with mantle cell lymphoma or low-grade B-cell non-Hodgkin lymphoma that has returned or stopped responding to other treatments. The main goal is to find the safest…

This study is testing a combination of two drugs, ibrutinib and rituximab, for people with mantle cell lymphoma, a type of blood cancer. It is for two groups: those whose cancer has returned or hasn't responded to prior treatment, and older patients newly diagnosed with the disea…

This study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…